Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients

Tetsuya Yasunaka, Fusao Ikeda, Nozomu Wada, Yuki Morimoto, Shin ichi Fujioka, Junichi Toshimori, Haruhiko Kobashi, Kazuya Kariyama, Yoichi Morimoto, Hiroki Takayama, Tomonori Seno, Koichi Takaguchi, Akio Moriya, Hirokazu Miyatake, Ryoichi Okamoto, Kazuhisa Yabushita, Akinobu Takaki, Kazuhide Yamamoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients grouped by age, hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and treatment. HCCs were observed in 115 patients with the median observation period of 1,687 days. Among the HCC patients aged ≥ 35 years, HBV DNA ≥ 4 log copies/mL and positive HBeAg at diagnosis (n=184), the HCC incidence rate was 8.4% at 5 years in the entecavir (ETV)-treated patients, 21.8% in the lamivudine (LVD)-treated patients, and 26.4% among the patients not treated with drugs. The cumulative HCC incidence was significantly reduced in the ETV-treated patients compared to those treated with LVD or not treated (p=0.013). Among the patients aged ≥ 35 years with HBV DNA ≥ 4 log copies/mL and negative HBeAg (n=237), the cumulative HCC incidence was 14.6% in 5 years in ETV group and 13.9% among those not treated with a drug (p>0.05). Only small numbers of HCCs occurred in other patients. In CHB patients aged 35 years with HBV DNA ≥ 4 log copies/mL and positive HBeAg, ETV treatment is recommended for the suppression of HCC development.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalActa Medica Okayama
Volume70
Issue number1
Publication statusPublished - 2016

Fingerprint

Hepatitis B e Antigens
Chronic Hepatitis B
Viruses
Lamivudine
DNA
Hepatocellular Carcinoma
Hepatitis B virus
Pharmaceutical Preparations
Incidence
entecavir
Fibrosis
Observation

Keywords

  • Entecavir
  • Hepatitis B virus
  • Hepatocellular carcinoma
  • Lamivudine

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Yasunaka, T., Ikeda, F., Wada, N., Morimoto, Y., Fujioka, S. I., Toshimori, J., ... Yamamoto, K. (2016). Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients. Acta Medica Okayama, 70(1), 1-12.

Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients. / Yasunaka, Tetsuya; Ikeda, Fusao; Wada, Nozomu; Morimoto, Yuki; Fujioka, Shin ichi; Toshimori, Junichi; Kobashi, Haruhiko; Kariyama, Kazuya; Morimoto, Yoichi; Takayama, Hiroki; Seno, Tomonori; Takaguchi, Koichi; Moriya, Akio; Miyatake, Hirokazu; Okamoto, Ryoichi; Yabushita, Kazuhisa; Takaki, Akinobu; Yamamoto, Kazuhide.

In: Acta Medica Okayama, Vol. 70, No. 1, 2016, p. 1-12.

Research output: Contribution to journalArticle

Yasunaka, T, Ikeda, F, Wada, N, Morimoto, Y, Fujioka, SI, Toshimori, J, Kobashi, H, Kariyama, K, Morimoto, Y, Takayama, H, Seno, T, Takaguchi, K, Moriya, A, Miyatake, H, Okamoto, R, Yabushita, K, Takaki, A & Yamamoto, K 2016, 'Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients', Acta Medica Okayama, vol. 70, no. 1, pp. 1-12.
Yasunaka T, Ikeda F, Wada N, Morimoto Y, Fujioka SI, Toshimori J et al. Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients. Acta Medica Okayama. 2016;70(1):1-12.
Yasunaka, Tetsuya ; Ikeda, Fusao ; Wada, Nozomu ; Morimoto, Yuki ; Fujioka, Shin ichi ; Toshimori, Junichi ; Kobashi, Haruhiko ; Kariyama, Kazuya ; Morimoto, Yoichi ; Takayama, Hiroki ; Seno, Tomonori ; Takaguchi, Koichi ; Moriya, Akio ; Miyatake, Hirokazu ; Okamoto, Ryoichi ; Yabushita, Kazuhisa ; Takaki, Akinobu ; Yamamoto, Kazuhide. / Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients. In: Acta Medica Okayama. 2016 ; Vol. 70, No. 1. pp. 1-12.
@article{971247b43f284715a5552d42d940892d,
title = "Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients",
abstract = "Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients grouped by age, hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and treatment. HCCs were observed in 115 patients with the median observation period of 1,687 days. Among the HCC patients aged ≥ 35 years, HBV DNA ≥ 4 log copies/mL and positive HBeAg at diagnosis (n=184), the HCC incidence rate was 8.4{\%} at 5 years in the entecavir (ETV)-treated patients, 21.8{\%} in the lamivudine (LVD)-treated patients, and 26.4{\%} among the patients not treated with drugs. The cumulative HCC incidence was significantly reduced in the ETV-treated patients compared to those treated with LVD or not treated (p=0.013). Among the patients aged ≥ 35 years with HBV DNA ≥ 4 log copies/mL and negative HBeAg (n=237), the cumulative HCC incidence was 14.6{\%} in 5 years in ETV group and 13.9{\%} among those not treated with a drug (p>0.05). Only small numbers of HCCs occurred in other patients. In CHB patients aged 35 years with HBV DNA ≥ 4 log copies/mL and positive HBeAg, ETV treatment is recommended for the suppression of HCC development.",
keywords = "Entecavir, Hepatitis B virus, Hepatocellular carcinoma, Lamivudine",
author = "Tetsuya Yasunaka and Fusao Ikeda and Nozomu Wada and Yuki Morimoto and Fujioka, {Shin ichi} and Junichi Toshimori and Haruhiko Kobashi and Kazuya Kariyama and Yoichi Morimoto and Hiroki Takayama and Tomonori Seno and Koichi Takaguchi and Akio Moriya and Hirokazu Miyatake and Ryoichi Okamoto and Kazuhisa Yabushita and Akinobu Takaki and Kazuhide Yamamoto",
year = "2016",
language = "English",
volume = "70",
pages = "1--12",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "1",

}

TY - JOUR

T1 - Entecavir reduces hepatocarcinogenesis in chronic hepatitis B patients

AU - Yasunaka, Tetsuya

AU - Ikeda, Fusao

AU - Wada, Nozomu

AU - Morimoto, Yuki

AU - Fujioka, Shin ichi

AU - Toshimori, Junichi

AU - Kobashi, Haruhiko

AU - Kariyama, Kazuya

AU - Morimoto, Yoichi

AU - Takayama, Hiroki

AU - Seno, Tomonori

AU - Takaguchi, Koichi

AU - Moriya, Akio

AU - Miyatake, Hirokazu

AU - Okamoto, Ryoichi

AU - Yabushita, Kazuhisa

AU - Takaki, Akinobu

AU - Yamamoto, Kazuhide

PY - 2016

Y1 - 2016

N2 - Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients grouped by age, hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and treatment. HCCs were observed in 115 patients with the median observation period of 1,687 days. Among the HCC patients aged ≥ 35 years, HBV DNA ≥ 4 log copies/mL and positive HBeAg at diagnosis (n=184), the HCC incidence rate was 8.4% at 5 years in the entecavir (ETV)-treated patients, 21.8% in the lamivudine (LVD)-treated patients, and 26.4% among the patients not treated with drugs. The cumulative HCC incidence was significantly reduced in the ETV-treated patients compared to those treated with LVD or not treated (p=0.013). Among the patients aged ≥ 35 years with HBV DNA ≥ 4 log copies/mL and negative HBeAg (n=237), the cumulative HCC incidence was 14.6% in 5 years in ETV group and 13.9% among those not treated with a drug (p>0.05). Only small numbers of HCCs occurred in other patients. In CHB patients aged 35 years with HBV DNA ≥ 4 log copies/mL and positive HBeAg, ETV treatment is recommended for the suppression of HCC development.

AB - Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients grouped by age, hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and treatment. HCCs were observed in 115 patients with the median observation period of 1,687 days. Among the HCC patients aged ≥ 35 years, HBV DNA ≥ 4 log copies/mL and positive HBeAg at diagnosis (n=184), the HCC incidence rate was 8.4% at 5 years in the entecavir (ETV)-treated patients, 21.8% in the lamivudine (LVD)-treated patients, and 26.4% among the patients not treated with drugs. The cumulative HCC incidence was significantly reduced in the ETV-treated patients compared to those treated with LVD or not treated (p=0.013). Among the patients aged ≥ 35 years with HBV DNA ≥ 4 log copies/mL and negative HBeAg (n=237), the cumulative HCC incidence was 14.6% in 5 years in ETV group and 13.9% among those not treated with a drug (p>0.05). Only small numbers of HCCs occurred in other patients. In CHB patients aged 35 years with HBV DNA ≥ 4 log copies/mL and positive HBeAg, ETV treatment is recommended for the suppression of HCC development.

KW - Entecavir

KW - Hepatitis B virus

KW - Hepatocellular carcinoma

KW - Lamivudine

UR - http://www.scopus.com/inward/record.url?scp=84962271982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962271982&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 1

EP - 12

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 1

ER -